Loading…

Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2021-09, Vol.21, p.S202-S202
Main Authors:	Coombs, Catherine C., Pagel, John M., Shah, Nirav N., Lamanna, Nicole, Lech-Maranda, Ewa, Eyre, Toby A., Woyach, Jennifer A., Wierda, William G, Cheah, Chan Y., Roeker, Lindsey, Patel, Manish R., Fakhri, Bita, Barve, Minal A., Tam, Constantine S., Lewis, David J., Gerson, James N., Alencar, Alvaro, Taylor, Justin, Abdel-Wahab, Omar, Ghia, Paolo, Schuster, Stephen J., Chen, Jessica, Nair, Binoj, Tsai, Donald E., Ku, Nora C., Davids, Matthew S., Brown, Jennifer R., Jurczak, Wojciech, Mato, Anthony R.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!